Targets under examination include epithelial cell adhesion molecule (EpCAM) in non-small cell lung carcinoma, glycan 3 (GPC3) in live cancer, HER2 in breast cancer, and prostate-specific membrane antigen (PSMA) in prostate cancer [9]. Here, ERBB2 is linked to breast cancer.